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Abstract
Purpose We aimed to achieve a retrospective molecular diag-
nosis by applying state-of-the-art genomic sequencing
methods to past patients with T-B+NK+ severe combined im-
munodeficiency (SCID). We included identification of copy
number variations (CNVs) by whole exome sequencing
(WES) using the CNV calling method ExomeDepth to detect
gene alterations for which routine Sanger sequencing analysis
is not suitable, such as large heterozygous deletions.
Methods Of a total of 12 undiagnosed patients with T-B+NK+
SCID, we analyzed eight probands by WES, using GATK to
detect single nucleotide variants (SNVs) and small insertions
and deletions (INDELs) and ExomeDepth to detect CNVs.
Results We found heterozygous single- or multi-exon dele-
tions in IL7R, a known disease gene for autosomal recessive
T-B+NK+ SCID, in four families (seven patients). In three
families (five patients), these deletions coexisted with a het-
erozygous splice site or nonsense mutation elsewhere in the
same gene, consistent with compound heterozygosity. In our
cohort, about a quarter of T-B+NK+ SCID patients (26%) had
such compound heterozygous IL7R deletions.
Conclusions We show that heterozygous IL7R exon deletions
are common in T-B+NK+ SCID and are detectable by WES.
They should be considered if Sanger sequencing fails to detect
homozygous or compound heterozygous IL7R SNVs or
INDELs.
Keywords IL7R . copy number variation . compound
heterozygous . SCID . whole exome sequencing
Introduction
Whole exome sequencing (WES) is a powerful tool for discov-
ering pathogenic variants in rare genetic diseases, detecting both
single nucleotide variants (SNVs) and small insertions/deletions
in known disease genes with relative efficiency. WES has not
been seen as offering equivalent advantages for the detection of
copy number variations (CNVs), which instead may be sought
by chromosomal microarrays or multiplex ligation-dependent
probe amplification (MLPA). However, recent computational
advances have also made it possible to identify CNVs by
WES [1, 2]. This is of great advantage as limitations of array-
based CNV detection methods, such as noisy signal and low
resolution, make detection of small CNVs difficult, and large
heterozygous deletions can only be detected by conventional
PCR-based sequencing methods using genomic DNA if the
breakpoints of the deletion are known. Therefore, routine
Sanger sequencing analysis is not suitable for the detection of
such gene alterations.
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In our center, we have treated a cohort of 19 patients
with T-B+NK+ severe combined immunodeficiency
(SCID), characterized by early symptoms of immunodefi-
ciency (such as failure to thrive and recurrent infections),
and/or a positive family history of T-B+NK+ SCID, to-
gether with profound T lymphocytopenia, low serum im-
munoglobulin levels and impaired lymphocyte prolifera-
tion to mitogens. Autosomal recessive (AR) mutations in
several genes have been reported to cause T-B+NK+
SCID. Amongst these are CD3E, CD3D and CD3Z, all
of which encode subunits of the CD3/T cell receptor com-
plex [3, 4], as well as IL7R [5], which encodes IL7Rα,
commonly known as IL7R, the unique alpha chain of the
heterodimeric receptor for interleukin-7 (IL-7). IL-7 is
necessary for T lymphocyte development in the thymus
and for proliferation and survival of T lymphocytes in the
periphery [6, 7]. Coronin-1A deficiency due to AR muta-
tions in CORO1A can cause T-B+NK+ SCID through im-
paired actin cytoskeleton regulation [8–10]. Coronin-1A
is an actin-binding protein required for lymphocyte migra-
tion and thymic egress. The human Nude/T-B+NK+ SCID
phenotype is caused by mutations in the gene FOXN1,
which encodes a transcription factor crucial for thymus
development [11, 12]. An autosomal dominant T cell dif-
ferentiation defect due to congenital absence of the thy-
mus can be found in ‘complete’ chromosome 22q11.2
deletion syndrome (DiGeorge syndrome), in which the
immunodeficiency is usually part of a clinical triad also
including congenital cardiac and parathyroid gland defects
[13].
IL7R deficiency had been diagnosed in seven patients of
our cohort of non-syndromic T-B+NK+ SCID by convention-
al methods (Fig. 1). The remaining 12 patients from eight
families were screened by WES to identify disease-causing
mutations, resulting in the molecular diagnosis of ten patients.
Here, we show successful detection by WES of heterozy-
gous single- or multi-exon deletions in the gene IL7R, invisi-
ble by conventional sequencing techniques, in patients with T-
B+NK+ SCID.
Methods
Study Subjects
Patients and their relatives provided written informed con-
sent to participate in research protocols approved by the
Newcastle and North Tyneside 1 Research Ethics
Committee. Whole blood samples, buccal samples or der-
mal fibroblast cultures were obtained from these individ-
uals, and genomic DNA was isolated using the DNeasy or
QIAamp DNA mini kit (Qiagen).
PCR and Sequencing Analysis
Specific primers were designed in Primer3web version 4.0.0
(http://bioinfo.ut.ee/primer3/). Primer sequences are available
on request. Capillary sequencing was performed according to
standardmethods. Sequences were aligned with the consensus
coding sequence (human genome assembly 37 in nucleotide
BLAST (http://blast.ncbi.nlm.nih.gov/blast/). ChromasLite
Version 2.1.1 was used for visualization of the sequences.
WES and CNVAnalysis
Whole exomes of the patients were enriched with the Agilent
SureSelect Human All Exon V5 kit (Santa Clara, CA, USA)
and subsequently sequenced using the Illumina HiSeq 2500
sequencing system (San Diego, CA, USA) by AROS
(Applied Biotechnology AS, Denmark). Sequencing reads
were analyzed using the following workflow to identify vari-
ants in patients. Firstly, the quality of sequencing reads was
checked with FastQC (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/). Duplicated reads were removed with
FastUniq [14]. The remaining reads were mapped to the
human reference genome GRCh37 with BWA [15]. The
alignments were refined with tools of the GATK suite [16].
Variants were called according to GATK Best Practice
recommendations [17, 18], including recalibration, as well
as using Freebayes [19]. The variants called by Freebayes
with total coverage ≥5, minor allele coverage ≥5 and variant
call quality ≥20 were added to those identified by GATK.
Non-synonymous exonic variants were subsequently filtered
by quality and minor-allele frequency (MAF) reported in the
1000 Genomes project (2012 Feb release) [20] and ESP6500
[21]. Variants with MAF >0.05 were excluded. Annovar was
used for annotations and prediction of functional conse-
quences [22]. Copy number variants (CNVs) were called
using ExomeDepth from the GATK refined alignments [1].
Lymphocyte Proliferation
Lymphocy t e p ro l i f e r a t i on in v i t r o t o mi togen
phytohaemagglutinin (PHA) was assayed by tritiated thymi-
dine incorporation in an accredited clinical laboratory using
standard techniques.
IL-7Rα Expression
Five microliters of anti-human CD127 PE (IL7Rα) (BD
Biosciences) or matched isotype control (BD Biosciences)
was added to 100 μl of blood or 106 PBMCs, incubated for
10 min at room temperature. Cells were lysed with FACsLyse
(BD Biosciences) for 10 min, and the remaining cells were
washed with Cell Wash (BD Biosciences) before being fixed
(FACsFix, BD Bioscience). Ten thousand lymphocytes were
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acquired (FACsCalibur, BD Biosciences) and analyzed (Cell
Quest Pro, BD Biosciences).
STAT5 Phosphorylation Assay
1 × 104 IU/ml IL-2 (Chiron), 50 ng/ml IL-15 (R&D systems)
or 10 ng/ml IL-7 (R&D Systems) were added to 100 ml of
whole blood or 106 PBMCs and placed at 37°C for 10 min to
stimulate cells. Two milliliters of prewarmed FACs Lyse/Fix
(BD Biosciences) were then added to the cells, mixed and
placed at 37°C for 10 min. The cells were pelleted and washed
once with STAT wash (phosphate-buffered saline containing
1 % fetal calf serum). The cells were resupended in cold Perm
Buffer III (BD Biosciences) and placed at 4°C for 30 min. The
cells were then washed once with STAT wash before 5 ml of
antibodies (STAT5 ptyr, and CD4 PerCP (BD Biosciences)
were added, and the cells were incubated at room temperature
for 30 min in the dark, washed with STAT wash and fixed
(FACsFix, BD Biosciences). Ten thousand lymphocyte events
were acquired (FACsCalibur, BD Biosciences) and analyzed
using CellQuest software (BD Biosciences).
Results
Case Summaries
Patient 6.1 presented at age 3 months with diarrhea and failure
to thrive (Table 1). Diagnosis was made at the age of
10 months, when he additionally presented with superficial
candidiasis and lymphocytopenia with absent T lymphocytes.
Patient 6.2 is the sister of patient 6.1 and was diagnosed short-
ly after birth because of family history, low lymphocyte num-
bers and weak proliferative responses to mitogen. Patient 7.1
presented with recurrent febrile episodes from the age of
1 month. At 7 months, persistent rotavirus gastroenteritis
and weight loss were documented. At 8 months, he was ad-
mitted to hospital with pneumocystis jirovecii pneumonia and
the diagnosis of SCID was made. Patient 7.2 is the brother of
patient 7.1 and was diagnosed shortly after birth because of
family history, absent T cells and low lymphocyte prolifera-
tion. Patient 8 presented at the age of 5 months with progres-
sive cough, vomiting, poor appetite and then failure to thrive.
Diagnosis was made at age of 8 months, when she was admit-
ted to the hospital with pneumocystis jirovecii pneumonia and
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Fig. 1 Workflow and findings of
patient analysis. The first column
shows molecular analysis before
whole exome sequencing (WES)
for 19 patients from 14 families.
Rectangles contain either single
patients (x) or siblings (x.1, x.2).
If in a family only one sibling was
analyzed, his or her number is
shown in bold. Patients who had
either not been previously
analyzed or for whom no
causative mutation had been
found (findings shown in red)
were subjected to WES (second
column). For two patients,
cryopreserved PBMCs were
available for functional testing
(third column). Het.
heterozygous; Ex3del deletion of
exon 3; Ex2_4del deletion of
exons 2-4
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respiratory syncytial virus pneumonitis. Patient 12.1 presented
at the age of 3 months with recurrent chest infections, oral
candidiasis and failure to thrive. He was diagnosed as having
SCID at the age of 8 months. Patient 12.2 is the brother of
patient 12.1 and was diagnosed shortly after birth because of
family history, absent T cells and low lymphocyte
proliferation.
Whole Exome Sequencing Results
In two patients, we found homozygous loss-of-function mu-
tations in CD3 chains. In patient 9, the mutation was in CD3E
(c.424delG; p.G142fsX162), and in patient 14 in CD3D
(c.202C>T; p.R68X). Two siblings had a homozygous frame-
shift deletion in IL7R (c.493delC; p.H165fsX167; family 11)
(data not shown). These homozygous variants are predicted to
be disease-causing in each case. Patient 13 had a compound
heterozygous mutation in IL7R (heterozygous c.221+2T>G
and heterozygous c.76C>T, p.Q26X) (data not shown).
Several splice site prediction programs predict disruption of
the exon 2 splice donor site due to the c.221+2T>G mutation
(Table S1). Furthermore, a similar mutation (heterozygous
c.221+2T>A) together with a heterozygous missense muta-
tion in IL7R was found by Lee et al. in a patient with T-B+
SCID [23]. Thus, compound heterozygosity for these variants
could be considered causative.
WES sequencing of patients 6.2, 7.2, 8 and 12.2 from the
remaining four kindreds revealed a previously undetected het-
erozygous deletion of one or three exons of IL7R, coexisting
with heterozygous SNVs elsewhere in the same gene (Fig. 2).
Patients 6.2 and 8 had a heterozygous deletion of exon 3
(Ex3del) together with a heterozygous exon 2 splice donor
site mutation (c.221+2T>G). Patient 7.2 had a heterozygous
deletion of exons 2-4 (Ex2_4del) together with a nonsense
mutation in exon 1 (c.76C>A; p.Q26X). Patient 12.2 had a
heterozygous exon 3 deletion (Ex3del) together with hetero-
zygous SNVs at positions +6, +12 and +15 in the exon 7
splice donor site (c.876+6T>G; c.876+12T>G; c.876+
15T>G). The breakpoints in patients 6.2 and 7.2 were deter-
mined by Sanger sequencing (Figure S1), confirming the
WES finding of exon 3 or exon 2-4 hemizygosity, respective-
ly. Unfortunately, we were unable to define the exon 3 dele-
tion breakpoints in patients 8 and 12.2, which suggests that
they are different from that of family 6. Each of these exonic
deletions implies a frameshift with a premature stop codon: if
mRNAwere to escape nonsense-mediated decay, any protein
product would be severely truncated (84–95 %) with only a
small part of the extracellular domain left. Hence, all are pre-
dicted to be loss of function alleles.
In patients 6.2, 7.2 and 8, the heterozygous exonic deletion
we identified by WES accompanied a heterozygous SNV in
IL7R already identified by conventional diagnostic means and
predicted to be deleterious. We could not confirm compound
heterozygosity, as parental DNA was not available, but the
apposite phenotypes of the patients imply that the predicted
pathogenic IL7Rmutations found here are biallelic. In the case
of patient 8, cryopreserved PBMCs were available for func-
tional testing that confirmed absence of IL7R expression and
failure of STAT5 phosphorylation in response to IL-7
(Fig. 3c). This confirms the pathogenic nature of each allele,
i.e. both the heterozygous exon 3 deletion and the heterozy-
gous exon 2 splice donor site mutation c.221+2T>G produce
loss of function (Fig. 3b).
Of the three SNVs in the exon 7 splice donor site of patient
12.2, c.876+6T>G is predicted to have the strongest effect,
with Human Splicing Finder suggesting a broken donor site,
and BDGP detecting the splice donor site with a score of 0.46,
which is just above the threshold level of 0.4. The confidence
of NetGene2 that a splice donor site is present drops from 0.81
for the wild-type sequence to 0.62 for the region with all three
SNVs. However, the patient expressed IL7R at similar levels
to a healthy control (67 % patient vs. 78 % control) (Fig. 3b)
and sustained normal IL-7-induced STAT5 phosphorylation
(39 % in both patient and control) (Fig. 3c). Thus, either the
SNVs do not affect splicing or they are on the same allele as
the exon 3 deletion. Our molecular findings for kindred 12 do
not therefore explain the patients’ phenotype and emphasize
the importance of confirmatory functional testing for variants
of unknown significance.
Interestingly, in all patients that had a heterozygous IL7R
mutation detected by prior analysis, we found a complemen-
tary heterozygous IL7R exon(s) deletion (Fig. 1), emphasizing
the importance of looking for CNVs in IL7R in such cases. In
total, about a quarter of our patients (5/19, 26 %) had such
compound heterozygous IL7R deletions, with an additional
patient (12.2) being a carrier. In our cohort, the exon 2 splice
donor site mutation (c.221+2T>G) was most frequent, being
present in six alleles, followed by p.Q26X and Ex3del, which
were present in three alleles each.
Discussion
In recent years, the discovery of PID-causing genes has accel-
erated markedly due to advanced sequencing technologies.
Achieving a molecular diagnosis for individual patients with
PID can, however, still prove difficult even if the disease is
well defined and disease-causing genes are known. In our
center, one such disease was T-B+NK+ SCID. New patients
were directly analyzed byWES. Some patients were screened
by a targeted PID NGS panel that had not yet incorporated the
detection of CNVs. Older patients, for whom these technolo-
gies were not available at the time of presentation, were only
analyzed by Sanger sequencing. Of these, five patients did not
obtain a molecular diagnosis because only a single heterozy-
gous nonsense or splice site mutation in IL7Rwas found. Only
46 J Clin Immunol (2017) 37:42–50
when we applied WES with CNV detection by ExomeDepth
were we able to identify the cause of the disease in these five
patients, through detection of a heterozygous single- or multi-
exon deletion in IL7R as the second hit. Recently, Bayer et al.
applied WES together with custom-designed chromosomal
microarray to detect compound heterozygous mutations in
IL7R, which also included a heterozygous deletion of exon 3
[24]. We found three kindreds (at least two alleles) with a
deletion of exon 3, and one with a deletion of exons 2-4,
suggesting a deletion hotspot involving exon 3.
At both deletion breakpoints that we mapped, we detected
a microhomology of 2 and 3 bp, respectively (Figure S1 and
Table S2). Short stretches of 2–30 bp of microhomology at the
breakpoint sites are common in CNVs, with 70–80 % of
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Fig. 2 Compound heterozygous IL7R mutations. Mutation 1—
hemizygosity of exon 3 or exons 2-4 demonstrated by ExomeDepth.
Shown for each exon are peaks representing read depth (left) and the
observed to expected ratio of reads (right). Gray area expected value
range. Affected exons have fewer reads than those of other samples of
the same batch. Mutation 2—Sanger sequencing of heterozygous SNVs
(indicated in red)
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Fig. 3 The impact of the mutations on IL7R expression and IL-7 signal-
ing. a Schematic showing expected effect of the mutations on protein
expression. If, as the phenotype suggests, the mutations are in a com-
pound heterozygous setting, no patient would express full-length IL7R. b
IL7R expression was measured by flow cytometry on PBMCs from a
healthy control, patient 8 and patient 12.2. c STAT5 phosphorylation after
stimulation with IL-7 (red), IL-2 (green) and IL-15 (blue) for 10 min was
assessed by intracellular staining using whole blood or PBMCs from a
healthy control, patient 8 and patient 12.2
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human deletion CNVs showing microhomology [25, 26].
Interestingly, a third of microhomology stretches found in rare
pathogenic microdeletions were 2 or 3 bp long [26].
Formation of microhomology-associated microdeletions is
thought to be mediated by replication-based mechanisms such
as non-homologous end-joining (NHEJ), microhomology-
mediated end-joining (MMEJ) and fork stalling and template
switching (FoSTeS) [26]. In addition to the microhomology,
83 % of deletion CNVs have at least one breakpoint within a
known repetitive element [26]. The analysis of the four
breakpoint regions in our patients showed this to be true for
our deletion breakpoints too (Table S2). Breakpoint region 1
of the exon 3 deletion is within a long interspersed nuclear
element/L1 repeat, whereas breakpoint region 2 of the exon 2-
4 deletion is within a small interspersed nuclear element/Alu
repeat. The local genomic architecture in parts of the IL7R
gene may thus render it particularly susceptible to deletion
CNVs.
We found that single- or multi-exon deletions in IL7R are
relatively frequent disease alleles in autosomal recessive T-B+
NK+ SCID and can be detected by CNVanalysis. Without the
application of methods specifically to scrutinize CNVs, these
disease alleles would be missed in the heterozygous state. Our
cohort suggests that CNVanalysis would be required to reach
a molecular diagnosis in about a quarter of patients. Especially
for centers that already use WES or targeted gene panels, we
suggest they extend their analysis to include CNV detection.
Various techniques are already established so can be applied
without much difficulty. Coverage of IL7R by available whole
exome platforms is sufficient to call such variants using either
ExomeDepth or one of the other CNV calling methods sum-
marized in Tan et al. [2]. The same applies for targeted gene
panels that include IL7R; at Great Ormond Street Hospital, we
now use ExomeDepth for CNV detection in samples analyzed
with the targeted primary immunodeficiency gene panel.
Alternatively, MLPA analysis could be employed, as is rou-
tinely done in screening for Artemis deficiency [27].
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